US EditionPublished • loading... • Updated
Dr. Richard Pazdur Appointed to Lead FDA’s Drug Division After Turbulent Year
Dr. Pazdur, a 26-year FDA veteran, takes charge of CDER after 1,000 staff departures to stabilize drug approval processes and accelerate cancer treatment reviews.
- The FDA appointed Dr. Richard Pazdur to lead its main drug-approval division, placing him in charge of the Center for Drug Evaluation and Research, as of Nov. 13, 2025.
- After a year of heavy turnover, Center for Drug Evaluation and Research faced major staffing losses with about 1,000 departures this year among about 5,000 employees, following Dr. George Tidmarsh, predecessor's recent resignation.
- Known for backing surrogate endpoints, Dr. Richard Pazdur, 26-year FDA veteran, has sped cancer drug approvals and urged companies testing cancer drugs in China to repeat trials with U.S. patients.
- The change positions Dr. Richard Pazdur to influence approvals affecting cancer, rare and neurological disease patients, with observers saying his leadership brings stability and shapes drug trials conducted abroad.
- Amid promises of regulatory reform, Dr. Richard Pazdur said, `I'm honored to lead CDER at a time when the FDA is achieving long-sought regulatory reforms` as tensions rise after Dr. George Tidmarsh's criticisms and lawsuit.
Insights by Ground AI
21 Articles
21 Articles
Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry. This content is for Group 1 - Individual Seat, Individual Subscription - Annual ($555), Individual Subscription - Monthly ($55), Introductory Subscription - non-renew…
Coverage Details
Total News Sources21
Leaning Left4Leaning Right2Center4Last UpdatedBias Distribution40% Left, 40% Center
Bias Distribution
- 40% of the sources lean Left, 40% of the sources are Center
40% Center
L 40%
C 40%
R 20%
Factuality
To view factuality data please Upgrade to Premium
